XY Capital Ltd Sells 66,872 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

Key Points

• XY Capital Ltd reduced its stake in Takeda Pharmaceutical by 41.1%, now holding 95,830 shares valued at approximately $1.43 million.
• Takeda's most recent earnings report showed an EPS of $0.52, exceeding analysts' estimates of $0.47, despite quarterly revenue of $7.45 billion falling short of estimates.
• The company's stock is currently trading at $14.39, with a market capitalization of $45.77 billion and a P/E ratio of 47.95.

XY Capital Ltd lowered its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 41.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 95,830 shares of the company's stock after selling 66,872 shares during the quarter. Takeda Pharmaceutical makes up approximately 0.4% of XY Capital Ltd's portfolio, making the stock its 21st largest holding. XY Capital Ltd's holdings in Takeda Pharmaceutical were worth $1,425,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. LPL Financial LLC increased its position in shares of Takeda Pharmaceutical by 1.9% in the fourth quarter. LPL Financial LLC now owns 186,652 shares of the company's stock worth $2,471,000 after purchasing an additional 3,564 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Takeda Pharmaceutical by 94.5% in the fourth quarter. JPMorgan Chase & Co. now owns 83,826 shares of the company's stock worth $1,110,000 after purchasing an additional 40,721 shares during the last quarter. Orion Portfolio Solutions LLC bought a new position in shares of Takeda Pharmaceutical in the fourth quarter worth approximately $172,000. Franklin Resources Inc. lifted its stake in Takeda Pharmaceutical by 16.2% in the fourth quarter. Franklin Resources Inc. now owns 19,791 shares of the company's stock worth $262,000 after acquiring an additional 2,763 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in Takeda Pharmaceutical by 48.6% in the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock worth $600,000 after acquiring an additional 14,831 shares during the period. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Up 1.2%

Takeda Pharmaceutical stock traded up $0.18 on Tuesday, hitting $14.61. 2,303,348 shares of the stock traded hands, compared to its average volume of 2,517,132. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. The firm has a market cap of $46.47 billion, a P/E ratio of 48.68 and a beta of 0.22. The business's fifty day simple moving average is $14.81 and its 200 day simple moving average is $14.59. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.